Tuesday, January 25, 2022 Daily Archives

64x Bio bags $55m in funding to drive cell production tech

by

64x Bio has received $55 million in a series A round of fundraising to fund the expansion of its VectorSelect platform. According to 64x Bio, a synthetic cell and gene therapy (CGT) manufacturer founded in 2020 and focused on addressing CGT manufacturing issues exposed by the Coronavirus pandemic, its cell line engineering technology, VectorSector has the potential to revolutionize the economics and accessibility of gene therapy. Led by Lifeforce Capital, with contribution from Northpond Ventures, Future Ventures and others ,…

January 25, 2022

Excellos: ‘There is no better time to enter cell therapy CDMO space’

by

With the San Diego Blood Bank at its foundation and $15 million of funding in hand, Excellos launches itself in the cell therapy contract manufacturing sector.  A new contract development and manufacturing organization (CDMO) has arisen in San Diego, California this week: Excellos Incorporated, which officially launched on the back of $15 million in growth funding from Telegraph Hill Partners (THP).  The new entity — announced during Phacilitate’s Advanced Therapies Week conference in Miami, Florida — already has an operational cGMP manufacturing facility for Advanced Therapies but according to CEO…

January 25, 2022